Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors

European Heart Journal, Supplement

Volumn 7, Issue L, 2005, Pages

  Finer, Nick ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Anti obesity drugs; Cardiovascular risk; HDL cholesterol; Metabolic risk; Obesity; Orlistat; Rimonabant; Risk factors; Sibutramine; Weight loss

Indexed keywords

ANTIOBESITY AGENT; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL DISCOMFORT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DEFECATION DISORDER; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; GLUCOSE HOMEOSTASIS; HUMAN; LIFESTYLE; MALABSORPTION; OBESITY; PRIORITY JOURNAL; RISK FACTOR; WEIGHT REDUCTION;

EID: 27744443889     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui084     Document Type: Conference Paper

References (23)

1. Hansen DL, Toubro S, Stock MJ et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016-1024.
2. Hansen DL, Toubro S, Stock MJ et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-1186.
3. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 1999;23:1009-1015.
4. James WP, Astrup A, Finer N et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-2125.
5. Webber J. Energy balance in obesity. Proc Nutr Soc 2003;62:539-543.
6. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997;21(Suppl. 3):S12-S23.
7. Horvath TL. Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 2003;112:323-326.
8. Apfelbaum M, Vague P, Ziegler O et al. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184.
9. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care 2004;27:155-161.
10. Van Gaal LF, Rissanen AM, Scheen AJ et al.; for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397.
11. Chong E. Weight loss produced by sibutramine: a meta-analysis. Int J Obes Relat Metab Disord 2001;25(Suppl. 2):S104.
12. O'Meara S, Riemsma R, Shirran L et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5(18):1-81.
13. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese Type 2 diabetic patients treated with metformin. Diabetes Care 2003;26:125-131.
14. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136-145.
15. Sharma AM. Sibutramine in overweight/obese hypertensive patients. Int J Obes Relat Metab Disord 2001;25(Suppl. 4):S20-S23.
16. Sjöström L, Lindroos AK, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693.
17. Rossner S, Sjostrom L, Noack R et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:49-61.
18. Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int J Obes Relat Metab Disord 1998;22(Suppl. 1):S38-S40.
19. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.
20. Sjöström L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-172.
21. Muls E, Kolanowski J, Scheen A et al.; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25:1713-1721.
22. Abbott Laboratories. Data on file.
23. Kelley DE, Kuller LH, McKolanis TM et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in Type 2 diabetes. Diabetes Care 2004;27:33-40.